Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy

Cancer

Volumn 86, Issue 6, 1999, Pages 976-981

  Jimenez, Rafael E ^a   Zalupski, Mark M ^a   Frank, John J ^a   Du, Wei ^a   Ryan, James R ^b   Lucas, David R ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

C494; Chemoresistance; Chemotherapy; JSB 1; MDR; P glycoprotein; Soft tissue sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; EPITOPE; GLYCOPROTEIN P; IFOSFAMIDE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TUMOR NECROSIS;

EID: 0033568161     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990915)86:6<976::AID-CNCR12>3.0.CO;2-3     Document Type: Article

References (28)

1. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996; 192:768-80.
2. Mertens WC, Bramwell VHC. Adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin North Am 1995;9: 801-15.
3. Zalupski MM, Baker LH. Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin North Am 1995;9:787-800.
4. Fojo AT, Ueda K, Slamon DJ, Ppoplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-9.
5. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
6. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WAS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
7. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-5.
8. Klein EA. The multidrug resistance gene in renal cell carcinoma. Semin Urol 1989;7:207-14.
9. Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression of MDR1 and glutatione S transferase-p; genes and chemosensitivities in human gastrointestinal cancer. Cancer 1992;69:941-6.
10. Huang C, Wu M, Xu G, Li D, Cheng H, Tu Z, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992;84:262-3.
11. Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-p in human breast tumors: comparison to in vitro chemosensitivity. Br J Cancer 1990;61:712-6.
12. Volm M, Mattem J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase-p; in resistant non-small cell lung carcinomas of smokers. Br J Cancer 1991;64: 700-4.
13. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
14. Chan HSL, DeBoer G, Haddad G, Ling V. Multidrug drug resistance in pediatric sarcomas. Hematol Oncol Clin North Am 1995;9:889-908.
15. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
16. Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 1994;17:480-4.
17. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, et al. A phase III comparison of doxorubicin and DTIC given by bolus vs. infusion in patients with soft tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926-32.
18. Glasser DB, Lan JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992; 69:698-708.
19. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
20. Stein U, Shoemaker RH, Schlag PM. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 1996;32A:86-92.
21. Leuschner I, Schmidt D, Hoffman H, Dietel M, Harms D. Expression of P-glycoprotein in soft tissue tumors of childhood: correlation to treatment response [abstract]. J Cancer Res Clin Oncol 1991;117(Suppl III):97.
22. Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 1997;123:352-6.
23. Vergier B, Cany L, Bonnet F, Robert J, de Mascare A, Coindre JM. Expression of MDR1/P-glycoprotein in human sarcomas. Br J Cancer 1993;68:1221-6.
24. Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 1993;29A:1979-81.
25. Noonan KE, Beck C, Hozmayer TA, Chin JE, Wunder JS, Andrulis IL, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-4.
26. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987;5:1452-60.
27. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, Mankin HJ. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 1996;78-A: 366-75.
28. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.